Revenue segments as reported by the company.

Smokeable Products

Oral Tobacco Products

Wine

All Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, administration and research costs

Asset impairment and exit costs

Amortization of intangibles

General corporate expenses

Corporate asset impairment and exit costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Altria

Altria Group, Inc. operates as a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral tobacco products, and Wine. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral tobacco products segment is primarily moist smokeless tobacco products (MSTs) through brands like Copenhagen and Skoal as well as on! oral nicotine pouches sold by Helix. The Wine segment, through subsidiary Ste. Michelle Wine Estates Ltd, produces Washington State wines, primarily Chateau Ste. Michelle and 14 Hands, and owns wineries in or distributes wines from several other wine regions. The company was founded in 1919 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altria reports robust Q4 earnings, focuses on innovation and growth

Altria's Q4 2022 performance reflects resilience amidst industry challenges, with a focus on innovation and shareholder returns. The company's strategic initiatives in smoke-free products and digital engagement underscore its commitment to long-term growth and harm reduction.

Altria reports resilient Q1 performance amid industry challenges and opportunities

Altria's Q1 2023 earnings call highlighted strong performance amidst industry challenges, emphasizing harm reduction and regulatory compliance. The company faces hurdles from inflation, regulatory changes, and evolving consumer behaviors, while focusing on growth opportunities in smoke-free products and strategic investments.

Altria reports solid Q2 earnings, eyes e-vapor growth opportunities

Altria's focus on smoke-free products and NJOY acquisition driving growth.
Challenges in the cigarette industry due to economic pressures and flavor bans.
Opportunities in the e-vapor category and expansion plans in the U.S.
Strong balance sheet and significant capital returns to shareholders.

Altria reports growth in earnings, navigates regulatory challenges in e-vapor

Altria's Q3 2023 earnings call highlighted solid financial performance, strategic focus on e-vapor products, and efforts to combat illegal vape products. The company faces challenges from regulatory uncertainties and illicit products but sees opportunities in expanding NJOY's reach and addressing market gaps.

Altria reports growth in smoke-free products amidst regulatory challenges

Altria's Q4 2023 earnings call highlighted growth in adjusted EPS, strategic focus on smoke-free products, and efforts to combat illicit e-vapor products. The company faces challenges in competitive segments and economic pressures but sees opportunities in new product introductions and regulatory collaborations.

Altria reports mixed Q1 performance, focuses on growth strategies

Altria's Q1 performance showed growth in NJOY and oral tobacco segments, with challenges in EPS decline and economic pressures on consumers.
Strengths include reaffirmed EPS guidance, strategic investments, and focus on combating illicit e-vapor products.
Opportunities lie in maximizing profitability in oral tobacco, product positioning, and capturing transitioning consumers.
Overall, Altria's performance reflects a mix of growth, challenges, and strategic opportunities in navigating market dynamics.

Altria's NJOY drives growth as company navigates e-vapor challenges

Altria's Q2 2024 earnings call showcased strong performance in smoke-free products, highlighting growth in retail share and volume momentum. Despite challenges in the e-vapor category, the company remains focused on responsible regulation and enforcement. With a commitment to shareholder value and long-term growth strategies, Altria is poised for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria has paid out less than 80% of its adjusted earnings per share between FY 2017-2021. The company is expected to generate modest EPS growth in the next three years, ranging between 4-5% annually.

The Final Word: Altria's Dividend Is Not At Risk

Juul Labs Inc is seeking fresh financing at a time when the company is navigating uncertainty due to lawsuits and a potential ban on sales of its e-cigarettes by U.S. health regulators, Bloomberg News reported on Friday.

E-cigarette maker Juul seeks new financing - Bloomberg News

Abbott Labs

H.B. Fuller

Lowe's

MSA Safety

Parker-Hannifin

PPG Industries

Stanley Black & Decker

Sysco

Target

Tennant

The 44 Dividend Kings finished June in the red, collectively losing 5.39%. Last month, the 11 best dividend kings based on forecasted growth and valuation underperformed the average dividend king return by 152 bps.

My 11 Best Dividend Kings For July 2022

RICHMOND, Va.--(BUSINESS WIRE)---- $MO #ALTRIA--ALTRIA TO HOST WEBCAST OF 2022 SECOND-QUARTER RESULTS

Altria to Host Webcast of 2022 Second-Quarter and First-Half Results

Allianz SE

Bank of Nova Scotia

British American Tobacco

Enbridge

Enterprise Products Partners

Legal & General Group PLC

Manulife Financial

Magellan Midstream Partners

ONEOK

Pembina Pipeline

AT&T

AT&T has been one of the worst investments of the last decade, delivering about 2% inflation-adjusted annual total returns. Terrible management decisions and expensive debt-funded empire building resulted in the dividend getting almost cut in half and new management vowing to return to its telecom roots.

11 Higher-Yielding And Far Better Blue-Chip Alternatives To AT&T

The bad news for Altria never seems to end, with the FDA now proposing to ban JUUL E-cigarettes, thereby sending the share price plunging. This comes after Altria's flagship reduced-risk product, IQOS, was also banned, and the Biden administration is seeking to reduce nicotine levels in cigarettes to non-addictive levels.

Altria: Time To Start Thinking About The End Of The Dividend

My investment philosophy is heavily influenced by Ray Dalio, and this article elaborates on the role of geographical diversification. You will see why such consideration lead me to own British American Tobacco but not Altria, even though I think both are excellent businesses.

Altria, British American Tobacco, And Ray Dalio Positions

In the Juul litigation, what happens remains to be seen, but we expect the company to prevail. The company's price drop means it has an almost 9% dividend yield on top of continued share repurchases.

Altria: Stop Caring About Juul

Altria has seen its shares drop due to worries about its JUUL stake. But even an outright product ban for JUUL does not justify a $29 billion market cap decline. MO stock is trading at an extremely low valuation today and is priced for a perpetual decline. That does not align with what management forecasts and with what Wall Street expects.

Altria: It's Time To Buy The Panic In This 9%-Yielder Before The Next Dividend Increase

AbbVie

Federal Realty Investment Trust

Kimberly-Clark

Leggett & Platt

Universal Corp

Every time a bullish market commentator says things are fine, you can almost count on the market going into a tailspin.

The 7 Highest-Yielding Dividend Kings to Buy Now and Hold Forever

An FDA ruling and analysts' downgrades sent shares into a tailspin. However, Juul, the focus of the FDA ban, has been a net negative for Altria.

Altria Crashed: With A Yield Near 9%, Is It A Smoking Hot Pick Or A Melting Ice Cube?

Altria Group is going thru a legal battle as well as a struggle between the bulls and bears. Some view the chaos as an opportunity, while others are less optimistic.

Altria Group (NYSE MO): A Contentious High-Yield Dividend Stock

Devon Energy

Kinder Morgan

Simon Property Group

Williams

Investors love dividend stocks. They not only provide dependable income, but they also give investors a great opportunity for solid total return.

The Highest Paying S&P 500 Dividend Stocks Also May Be Among the Best Second-Half Ideas

The proposed FDA ban for Juul e-cigarettes has weighed on Altria's valuation in June and July. The FDA just stayed its ban. Juul Labs will challenge the FDA e-cigarette ban in court.

The Market Is Wrong About Altria's 8.8% Yield

Johnson & Johnson

Lockheed Martin

PepsiCo

Pfizer

Philip Morris

Unilever

As market volatility continues, these seven defensive names are some of the best bear market stocks to buy. The post 7 Best Bear Market Stocks to Buy in July 2022 appeared first on InvestorPlace.

7 Best Bear Market Stocks to Buy in July 2022

Polaris

Bear markets are terrifying, exhilarating, and when 80% of long-term fortunes are made. Today some of the world's greatest dividend stocks are table-pounding, Buffett-style "fat pitch" ultra-value buys.

3 Incredible July 4th Dividend Aristocrat Bargains

Cannabis is an area it may end up focusing more on.

Could Juul's Problems Make This an Inevitable Move for Altria?

There are "scientific issues" unique to Juul's application to stay on the market, the FDA says, which temporarily halts last month's order.

FDA Puts Juul Ban on Hold

WASHINGTON — The Food and Drug Administration and Juul agreed Wednesday to put their court fight on hold while the government conducts more review of the company's electronic cigarettes.

Juul, FDA suspend court fight while government reviews e-cigarettes

Amazon

Spirit Airlines

Could these consumer discretionary stocks be top picks for investors as markets seek direction?

Good Stocks To Buy Right Now? 3 Consumer Discretionary Stocks In Focus

Altria Group Inc (NYSE: MO) shares are trading higher Wednesday after the U.S. Food and Drug Administration temporarily suspended the ban of Juul e-cigarette sales. "On July 5, 2022, FDA administratively stayed the marketing denial order.

What's Going On With Altria Stock Today?

Altria Group Inc (NYSE:MO) is up 1.6% at $42.37, after the U.S. Food and Drug Administration (FDA) said it was temporarily lifting its ban on Juul e-cigarette products as it conducts an additional review of Juul's marketing application.

Altria Stock Pops on FDA's Latest Juul Update

Resolute Forest Products

Find out how these stocks are handling a flattish market.

Altria Gets a Reprieve, but This Stock's the Real Wednesday Winner

Coinbase

Union Pacific and RingCentral are among other stocks making moves this morning.

Coinbase, Altria, and More Wednesday Morning Stock Movers

Best Buy

Gilead Sciences

Newell Brands

U.S. Bancorp

Finding stocks that are trading down after the worst first half for the S&P 500 in over 50 years is not hard these days.

6 Fallen Angel Stocks to Buy Now Will Continue to Pay Fat Dividends

News for Altria Stock (MO)